Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872434 | 0.77 | KMT2A (0.38) | CYP1A2ALDH1A1KMT2A | |
| SCHEMBL318966 | 0.70 | — | — | |
| SCHEMBL907735 | 0.67 | — | — | |
| SCHEMBL1859032 | 0.67 | — | — | |
| SCHEMBL3135272 | 0.67 | — | — | |
| SCHEMBL596463 | 0.67 | — | — | |
| SCHEMBL452030 | 0.67 | — | — | |
| SCHEMBL2800291 | 0.66 | MALT1 (0.31) | ALDH1A1 | |
| SCHEMBL7717522 | 0.64 | CYP1A2 (0.50) | CYP1A2ALDH1A1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL958642 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3041474-A1 | ANTIPROLIFERATIVE COMPOUNDS | Genentech, Inc. (US) | 2016-07-13 | — | — | EP | claimed |
| WO-2015035062-A1 | ANTIPROLIFERATIVE COMPOUNDS | GENENTECH, INC. (US) | 2015-03-12 | — | — | WO | claimed |
| US-20150065522-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2015-03-05 | — | — | US | claimed |
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | SB PHARMCO PUERTO RICO INC | 2011-07-14 | — | — | US | claimed |
| EP-1618107-B1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORK LTD (IE) | 2010-06-30 | — | — | EP | claimed |
| EP-2186813-A1 | Condensed N-heterocyclic compounds and their use as CRF receptor antagonists | SmithKline Beecham (Cork) Limited (IE) | 2010-05-19 | — | — | EP | claimed |
| EP-1695974-B1 | 1,8-Naphthyridines as CRF antagonists | GLAXO GROUP LTD (GB) | 2010-03-17 | — | — | EP | claimed |
| US-7462622-B2 | Pyrrolo[2, 3-d] pyrimidine derivatives as corticotropin releasing factor antagonists | GLAXO GROUP LIMITED (GB) | 2008-12-09 | — | — | US | claimed |
| EP-1383747-B1 | FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) | GLAXO GROUP LTD (GB) | 2008-02-20 | — | — | EP | claimed |
| US-7329667-B2 | A hexahydro-1,5,6,8-tetraaza-acenaphthylene or -1,3,4-triazaphenalene derivatives; treatment of depression and anxiety; inflammatory bowel disease; treatment of conditions mediated by corticotropin-releasing factor | GLAXO GROUP LIMITED (GB) | 2008-02-12 | — | — | US | claimed |
| WO-2002087573-A1 | CRF RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-11-07 | — | — | WO | claimed |
| WO-2002088095-A1 | FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) | GLAXO GROUP LIMITED (GB) | 2002-11-07 | — | — | WO | claimed |
| EP-1129091-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2002-10-02 | — | — | EP | claimed |
| CN-1328559-A | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES INC (US) | 2001-12-26 | — | — | CN | claimed |
| WO-2001087885-A1 | CRF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2001-11-22 | — | — | WO | claimed |
| EP-1129091-A2 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | Neurocrine Biosciences, Inc. (US) | 2001-09-05 | — | — | EP | claimed |
| US-6191131-B1 | PSYCHOLOGICAL, NERVOUS SYSTEM DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2001-02-20 | — | — | US | claimed |
| EP-1049699-A1 | AZOLO TRIAZINES AND PYRIMIDINES | Du Pont Pharmaceuticals Company (US) | 2000-11-08 | — | — | EP | claimed |
| WO-2000027846-A2 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2000-05-18 | — | — | WO | claimed |
| WO-1999038868-A1 | AZOLO TRIAZINES AND PYRIMIDINES | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-08-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | CRH, CRHR1, CRHR2 | CYP1A2 1490/4885ALDH1A1 3090/4885CYP3A4 1808/4885 |
| US-20150065522-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM5A, KDM5B, KDM5C | CYP1A2 888/4885ALDH1A1 595/4885CYP3A4 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.